Posted by Michael Wonder on 09 Jul 2021
ICER publishes evidence report on therapies for atopic dermatitis
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns about drugs in this class remain.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of the following therapies for atopic dermatitis:
- Abrocitinib (Pfizer)
- Tralokinumab (LEO Pharma)
- Baricitinib (Olumiant, Eli Lilly and Incyte)
- Upadacitinib monohydrate (Rinvoq, AbbVie)
- Ruxolitinib phosphate (Incyte)
- Dupilumab (Dupixent, Regeneron and Sanofi)
